EpilepsyGTx Secures $10M to Advance Breakthrough Gene Therapy for Focal Refractory Epilepsy
EpilepsyGTx, a pioneering biotechnology firm specializing in advanced gene therapies for focal refractory epilepsy, has announced a successful $10 million seed funding round. The financing, spearheaded by the UCL Technology Fund and bolstered by Health Technology Holding, marks a significant milestone in the company’s journey towards combating this challenging neurological disorder. Led by CEO Nicolas…